Iron’s Master Switch: How Cells and the Body Keep the Perfect Balance

Iron is the most abundant element on Earth by mass, and life has built itself around it. The same redox chemistry that lets iron shuttle electrons between oxidation states powers oxygen transport in hemoglobin, drives the mitochondrial enzymes that generate ATP, supports DNA synthesis and repair, and even participates in epigenetic regulation of gene expression. Yet that same reactivity makes iron dangerous. Free ferrous iron catalyzes the Fenton reaction, converting hydrogen peroxide into hydroxyl radicals that shred proteins, membranes, and DNA. Every organism therefore faces an exquisite balancing act: keep enough iron available for metabolism while ensuring that not a single atom more than necessary circulates freely. A new open-access review in Cellular and Molecular Life Sciences, authored by Laura Silvestri, Mariateresa Pettinato, Rossana Carleo, Valeria Furiosi, Antonella Nai, and Alessia Pagani of IRCCS Ospedale San Raffaele and collaborating institutions in Italy, maps the full architecture of this control system, from the molecular sensors inside individual cells to the liver-derived hormone that orchestrates iron traffic across the entire body.

At the cellular level, the master regulators are the iron regulatory proteins, IRP1 and IRP2, which operate through a remarkably elegant post-transcriptional circuit. These proteins bind to iron-responsive elements, or IREs, which are hairpin structures folded into the untranslated regions of specific messenger RNAs. When cellular iron is scarce, IRPs clamp onto IREs located near the start of transcripts, physically blocking the ribosome from translating them. This is how the cell silences production of ferritin, the iron-storage protein, and of ferroportin, the sole known iron exporter, ensuring that whatever iron is present stays inside the cell rather than being locked away or shipped out. Simultaneously, the same IRPs bind IREs in the 3-prime untranslated region of the transcript encoding transferrin receptor 1, the protein that imports iron-bound transferrin from the blood. There, binding stabilizes the mRNA against degradation, boosting receptor production and iron uptake. The result is a two-pronged switch: low iron turns on import and turns off export and storage, while iron abundance flips the entire program in the opposite direction.

The sensing mechanism itself is a story of molecular transformation. IRP1 is, in fact, a dual-function protein: when iron is plentiful, it assembles a 4Fe-4S iron-sulfur cluster into its active site and converts into cytosolic aconitase, an enzymatic relic of its evolutionary origin, losing its RNA-binding capacity in the process. When iron levels fall, the cluster disassembles and the protein reverts to its RNA-binding form. IRP2, which lacks the aconitase function, is regulated instead through iron-dependent degradation: in iron-replete conditions it is ubiquitinated following iron-dependent oxidation and destroyed by the proteasome. Two sensors, two mechanisms, one coherent output. This system also intersects with oxygen sensing, because hypoxia modulates IRP activity, linking iron availability to the oxygen-dependent metabolic state of the cell, a connection reflected in the review’s emphasis on hypoxia as a keyword of the field.

Cellular control, however, is only half the story. The body must decide globally how much iron to absorb from the diet, how much to release from storage, and how much to allocate to the single largest iron consumer: the erythron, the billions of developing red blood cells that require roughly twenty to twenty-five milligrams of iron daily in an adult human. Humans have no regulated route of iron excretion, so systemic balance is achieved almost entirely by controlling absorption at the duodenal enterocyte and release from iron-recycling macrophages. The linchpin of this control is hepcidin, a 25-amino-acid peptide hormone produced by the liver. Hepcidin binds to ferroportin on the surface of enterocytes, macrophages, and hepatocytes, triggering its internalization and degradation. With ferroportin removed, iron can neither leave the gut into the blood nor exit storage sites, and plasma iron falls. In effect, hepcidin is the body’s iron gatekeeper, and its concentration in plasma determines the flow of iron through the entire economy of the organism.

What makes hepcidin fascinating to researchers is the sophistication of its upstream wiring. The central signaling axis runs through the bone morphogenetic protein pathway: BMP6, produced in response to iron loading of liver sinusoidal endothelial cells, signals through SMAD transcription factors to switch on the HAMP gene encoding hepcidin. This pathway is tuned by a cast of accessory proteins. Hemojuvelin, encoded by HJV, acts as a co-receptor that amplifies BMP-SMAD signaling; mutations in HJV cause the most severe form of hereditary hemochromatosis, juvenile type, precisely because hepcidin production collapses. The transmembrane protease TMPRSS6, also known as matriptase-2, cleaves hemojuvelin from the cell surface, dampening the signal; loss-of-function mutations in TMPRSS6 produce iron-refractory iron deficiency anemia, a condition in which hepcidin remains inappropriately high and dietary iron cannot be absorbed. The review highlights FKBP12 as another layer of this circuit, a cytosolic protein that restrains BMP receptor signaling and thereby modulates hepcidin output, illustrating how finely the pathway is calibrated.

On top of the iron-sensing machinery sits a second regulatory layer that reads the body’s demand for iron. Transferrin receptor 2, a hepatocyte protein homologous to TFR1 but unable to bind IREs, senses the degree of transferrin saturation in plasma and transmits that information into the hepcidin pathway, working with the hemochromatosis protein HFE. Meanwhile, when red blood cell production accelerates, for example after hemorrhage, at altitude, or in response to anemia, erythroid cells in the bone marrow secrete erythroferrone, a hormone that suppresses hepcidin production, opening the ferroportin gates so that iron reserves can flow to the marrow. Inflammation adds yet another input: the cytokine interleukin-6 drives hepcidin up through the JAK-STAT pathway, sequestering iron in macrophages and hepatocytes and contributing to the anemia of chronic disease. The review’s central argument is that hepcidin regulation is not a single linear pathway but a dynamic integration hub, layering metabolic, stress, and environmental cues onto the core iron signal.

When these circuits fail, the clinical consequences are the disorders that have shaped human medicine for centuries. In hereditary hemochromatosis, mutations in HFE, TFR2, HJV, or hepcidin itself leave hepcidin inappropriately low relative to iron stores. Ferroportin stays active, dietary iron is absorbed relentlessly, and over decades the metal accumulates in the liver, pancreas, heart, and joints, causing cirrhosis, diabetes, cardiomyopathy, and arthritis if untreated. The disease illustrates the asymmetry of the system: because there is no excretory route, a small deficit in hepcidin translates into a lifelong positive iron balance. Conversely, when hepcidin is chronically elevated, as in inflammatory states or TMPRSS6 mutations, iron is locked away from the plasma and patients develop anemia that does not respond to oral iron supplementation, because the absorptive gate itself is closed.

Iron deficiency, the most common nutritional disorder worldwide, and iron overload thus represent opposite failures of the same regulatory logic, and understanding the circuits opens therapeutic doors. Drugs that stimulate the BMP-SMAD pathway or inhibit TMPRSS6 could raise hepcidin in beta-thalassemia and other iron-loading anemias, where suppressed hepcidin causes secondary overload even without transfusions. Conversely, hepcidin antagonists, including anti-hepcidin antibodies and BMP pathway inhibitors, could lower the hormone in anemia of inflammation, releasing iron trapped in macrophages. The review also points to emerging functions of iron-regulatory proteins that extend beyond their established roles, suggesting that IRPs and hepcidin pathway components participate in processes such as epigenetic regulation and stress responses, hinting that the iron system’s influence on physiology may be broader than the classical picture suggests.

What emerges from the synthesis is a picture of biological control at its most refined: a two-tier architecture in which every cell runs its own iron budget through post-transcriptional sensing, while a central hormonal circuit integrates stores, circulating iron, erythropoietic demand, inflammation, and hypoxia into a single systemic signal. The two tiers talk to each other, since ferroportin is both the target of hepcidin and an IRP-regulated transcript, creating feedback loops that span from the ribosome to the whole organism. For a field that began with the discovery of ferritin more than ninety years ago, the pace of discovery remains striking, and the Italian team’s comprehensive map arrives at a moment when hepcidin-targeted therapies are entering clinical development. Iron built the modern world of steel and oxygen, and inside our bodies, an equally engineered system of sensors, gates, and hormones keeps it in perfect, life-sustaining check.

Subject of Research: Molecular mechanisms of cellular and systemic iron homeostasis

Article Title: Circuits that guarantee iron homeostasis: from cellular sensing to systemic control

Article References: Silvestri, L., Pettinato, M., Carleo, R., Furiosi, V., Nai, A., & Pagani, A. (2026). Circuits that guarantee iron homeostasis: from cellular sensing to systemic control. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06422-8

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06422-8

Keywords: iron homeostasis, hepcidin, ferroportin, IRE-IRP system, transferrin receptor, BMP-SMAD pathway, TMPRSS6, hemochromatosis, iron deficiency, erythroferrone, hypoxia, gene regulation